Clinical trials: Ticagrelor
Healthy
Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor
The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.
- Trial name
- NCT01504906
- Testing
- cyclosporine, ticagrelor
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
In STEMI patients undergoing PPCI there is a delayed onset of action of oral P2Y12 receptor inhibitors, including prasugrel and ticagrelor.
- Trial name
- CANTIC (NCT03247738)
- Testing
- Cangrelor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Ischemic Stroke, Transient Ischemic Attack
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy…
- Trial name
- DEDAPT-TICA (NCT06653348)
- Testing
- Ticagrelor 60 + Aspirin, Ticagrelor 90 + aspirin
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences
Acute Coronary Syndrome (ACS)
Platelet Function in Patients With an Acute Coronary Syndrome
The aims of the study are to: explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome investigate whether a therapeutic window exist for novel platelet inhibitors…
- Trial name
- ATLANTIS-ACS (NCT01992484)
- Where
- Austria
- Volunteers
- 1,000 people
- Sponsor
- Medical University of Vienna
Acute Coronary Syndrome
Comparing Ticagrelor Versus Clopidogrel on Microcirculation
Recently, data (PLATO) from an AstraZeneca study of platelet inhibition and patient outcomes, a Phase III pivotal efficacy and safety study with a duration of up to 12 months comparing ticagrelor 90 mg twice daily dosing to…
- Trial name
- PLEIO (NCT02618733)
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Dong-A University
Bioavailability Heathy Volunteers
Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.
Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.
- Trial name
- NCT01887626
- Testing
- Ticagrelor 90 mg whole tablet, Ticagrelor 90 mg tablet crushed, Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cardiovascular Diseases
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)
The purpose of this randomized, cross-over study, is to ascertain if ticagrelor, but not prasugrel or clopidogrel, is associated to an improved endothelial function as assessed with peripheral arterial tonometry and markers of…
- Trial name
- HI-TECH (NCT02587260)
- Testing
- Ticagrelor, Prasugrel, Clopidogrel
- Where
- 5 sites in Italy, Netherlands and 2 more
- Volunteers
- 54 people
- Sponsor
- Erasmus Medical Center
Acute Coronary Syndrome
Central Apnea in Patients Receiving Ticagrelor
all patients with a left ventricular ejection fraction superior or equal to 50% less than 2 years after an acute coronary event and receiving ticagrelor will undergo a sleep polygraphy
- Trial name
- NCT03540459
- Testing
- sleep polygraphy
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Les Grands Prés
Coronary Artery Disease
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting.
- Trial name
- SWAP-5 (NCT04634162)
- Testing
- Cangrelor
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Florida
Bioequivalence, Healthy Japanese Subjects
Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects
This study will be an open-label, randomised, three-period, three-treatment, crossover study in healthy Japanese male and female of non-childbearing potential subjects, performed at a single study centre.
- Conditions
- Bioequivalence, Healthy Japanese Subjects, Pharmacokinetics
- Trial name
- NCT02436577
- Testing
- Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor IR tablet (90 mg) administered with 150 mL of water
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute ST Segment Elevation Myocardial Infarction, Thrombolysis in Myocardial Infarction Flow
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
Administration of Ticagrelor in patients with ST elevation myocardial infarction treated with pharmacological thrombolysis
- Trial name
- TREAT (NCT02298088)
- Testing
- Ticagrelor 180 mg, Clopidogrel
- Where
- 153 sites in Argentina, Australia and 8 more
- Volunteers
- 3,799 people
- Sponsor
- Hospital do Coracao
Peripheral Arterial Disease
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
This is a single center, prospective, randomized, unblinded, open-label, active controlled pilot study to evaluate the efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin in patients with Rutherford…
- Trial name
- NCT02230527
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Cleveland Clinic
Acute Coronary Syndrome
Platelet Reactivity After CABG
Patients who have a heart attack are regularly treated with either clopidogrel or ticagrelor. In a large clinical trial, treatment with ticagrelor before coronary bypass surgery (CABG) was associated with a lower risk of death…
- Trial name
- NCT01793597
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Vermont
Acute Coronary Syndrome
Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CABG in patients with acute coronary…
- Trial name
- TACSI (NCT03560310)
- Testing
- Ticagrelor 90mg twice daily and ASA 75-100 mg daily, ASA 75-160 mg daily
- Where
- 22 sites in Denmark, Finland and 3 more
- Volunteers
- 2,201 people
- Sponsor
- Vastra Gotaland Region
Diabetes Mellitus, Type 2, Coronary Artery Disease
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm.
- Trial name
- OPTIMUS-7 (NCT04484259)
- Testing
- Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Florida
Acute Coronary Syndrome
Canadian Ticagrelor Survey
This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns…
- Trial name
- NCT01757483
- Where
- Canada
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Coronary Heart Disease
Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease
The present study is aimed to determine the safety and efficacy of Ticagrelor single antiplatelet therapy (SAPT) in patients with primary coronary small vessel disease at high risk of bleeding after drug coated balloon (DCB)…
- Trial name
- NCT06088433
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Thrombosis
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender.
- Trial name
- NCT04945616
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Acute Coronary Syndrome
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes
The McGill University Health Center (MUHC) Division of Cardiology, with funding from the Canadian Institute of Health Research, is performing this randomized controlled trial to determine which dual antiplatelet therapy (DAPT)…
- Trial name
- TC4 (NCT04057300)
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, acetylsalicylic acid (ASA) 81mg
- Where
- Canada
- Volunteers
- 1,038 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre